12/27
06:04 am
bgne
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy [Yahoo! Finance]
Low
Report
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy [Yahoo! Finance]
12/27
06:00 am
bgne
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
Low
Report
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
12/24
06:18 am
bgne
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns [Yahoo! Finance]
Low
Report
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns [Yahoo! Finance]
12/23
06:00 am
bgne
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
12/12
07:30 pm
bgne
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
Medium
Report
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
12/9
08:32 pm
bgne
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets [Yahoo! Finance]
Medium
Report
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets [Yahoo! Finance]
12/9
08:30 pm
bgne
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
Medium
Report
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
12/4
06:12 am
bgne
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL [Yahoo! Finance]
Medium
Report
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL [Yahoo! Finance]
12/4
06:00 am
bgne
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
Low
Report
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
12/3
08:59 am
bgne
BeiGene, Ltd. (NASDAQ: BGNE) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $300.00 price target on the stock.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $300.00 price target on the stock.
12/2
06:01 am
bgne
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
Medium
Report
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
12/1
09:01 am
bgne
BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US [Seeking Alpha]
Medium
Report
BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US [Seeking Alpha]
11/27
06:06 am
bgne
European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer [Yahoo! Finance]
Low
Report
European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer [Yahoo! Finance]
11/27
06:00 am
bgne
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
Low
Report
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
11/26
06:01 am
bgne
BeiGene to Present at Upcoming Investor Conferences
Low
Report
BeiGene to Present at Upcoming Investor Conferences
11/21
03:09 am
bgne
BeiGene, Ltd. (NASDAQ: BGNE) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/19
06:00 am
bgne
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
Low
Report
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
11/14
06:00 am
bgne
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
Low
Report
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
11/14
12:02 am
bgne
BeiGene, Ltd. (NASDAQ: BGNE) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/13
01:46 pm
bgne
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $254.00 to $260.00. They now have a "buy" rating on the stock.
Low
Report
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $254.00 to $260.00. They now have a "buy" rating on the stock.
11/13
12:22 am
bgne
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight [Yahoo! Finance]
Low
Report
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight [Yahoo! Finance]
11/12
06:00 am
bgne
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
Low
Report
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
11/6
06:01 am
bgne
BeiGene to Present at the Jefferies London Healthcare Conference
Low
Report
BeiGene to Present at the Jefferies London Healthcare Conference
11/5
09:10 am
bgne
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 [Yahoo! Finance]
Low
Report
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 [Yahoo! Finance]
11/5
09:05 am
bgne
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
Low
Report
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024